Morgan Stanley upgraded Jazz Pharmaceuticals (JAZZ) to Overweight from Equal Weight with a $175 price target
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- ALX Oncology announces results from Phase 1b/2 trial
- Jazz Pharmaceuticals’ Ziihera now included in updated NCCN guidelines
- Jazz Pharmaceuticals (JAZZ) is Making Sweet Music with a Diverse Portfolio
- Roche announces FDA approval of label expansion into biliary tract cancer
- FDA grants accelerated approval to Jazz Pharmaceuticals’ Ziihera